Board Change • May 20
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Director Lianbo Zhang was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Annonce • Apr 25
Valiant Co.,Ltd, Annual General Meeting, May 21, 2026 Valiant Co.,Ltd, Annual General Meeting, May 21, 2026, at 14:00 China Standard Time. Location: The Company's Meeting Room, Yantai, Shandong China Annonce • Mar 31
Valiant Co.,Ltd to Report Q1, 2026 Results on Apr 25, 2026 Valiant Co.,Ltd announced that they will report Q1, 2026 results on Apr 25, 2026 Annonce • Dec 31
Valiant Co.,Ltd to Report Fiscal Year 2025 Results on Apr 25, 2026 Valiant Co.,Ltd announced that they will report fiscal year 2025 results on Apr 25, 2026 Annonce • Sep 30
Valiant Co.,Ltd to Report Q3, 2025 Results on Oct 27, 2025 Valiant Co.,Ltd announced that they will report Q3, 2025 results on Oct 27, 2025 Annonce • Jul 02
Valiant Co.,Ltd to Report First Half, 2025 Results on Aug 22, 2025 Valiant Co.,Ltd announced that they will report first half, 2025 results on Aug 22, 2025 Annonce • Apr 27
Valiant Co.,Ltd (SZSE:002643) announces an Equity Buyback for CNY 200 million worth of its shares. Valiant Co.,Ltd (SZSE:002643) announces a share repurchase program. Under the program, the company will repurchase up to CNY 200 million worth of class A common shares. The shares will be repurchased at a purchase price of CNY 16.55 per share. The purpose of the program is to reduce the company's registered capital. The program will be valid for 12 months. Annonce • Apr 25
Valiant Co.,Ltd, Annual General Meeting, May 21, 2025 Valiant Co.,Ltd, Annual General Meeting, May 21, 2025, at 14:00 China Standard Time. Location: The Company's Meeting Room, Yantai, Shandong China Annonce • Mar 31
Valiant Co.,Ltd to Report Q1, 2025 Results on Apr 25, 2025 Valiant Co.,Ltd announced that they will report Q1, 2025 results on Apr 25, 2025 Annonce • Dec 31
Valiant Co.,Ltd to Report Fiscal Year 2024 Results on Apr 25, 2025 Valiant Co.,Ltd announced that they will report fiscal year 2024 results on Apr 25, 2025 Buy Or Sell Opportunity • Nov 13
Now 20% undervalued Over the last 90 days, the stock has risen 28% to CN¥11.55. The fair value is estimated to be CN¥14.46, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 4.7% over the last 3 years. Earnings per share has declined by 6.5%. Revenue is forecast to grow by 33% in 2 years. Earnings are forecast to grow by 63% in the next 2 years. Reported Earnings • Oct 30
Third quarter 2024 earnings released: EPS: CN¥0.089 (vs CN¥0.20 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.089 (down from CN¥0.20 in 3Q 2023). Revenue: CN¥806.3m (down 27% from 3Q 2023). Net income: CN¥80.7m (down 57% from 3Q 2023). Profit margin: 10.0% (down from 17% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 19% per year, which means it is performing significantly worse than earnings. Buy Or Sell Opportunity • Oct 16
Now 20% undervalued Over the last 90 days, the stock has risen 6.1% to CN¥9.71. The fair value is estimated to be CN¥12.20, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 33% in 2 years. Earnings are forecast to grow by 51% in the next 2 years. Annonce • Sep 30
Valiant Co.,Ltd to Report Q3, 2024 Results on Oct 30, 2024 Valiant Co.,Ltd announced that they will report Q3, 2024 results on Oct 30, 2024 Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to CN¥9.43, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 16x in the Chemicals industry in China. Total loss to shareholders of 47% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥12.15 per share. Reported Earnings • Aug 22
Second quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.24 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.12 (down from CN¥0.24 in 2Q 2023). Revenue: CN¥1.02b (down 2.2% from 2Q 2023). Net income: CN¥116.9m (down 45% from 2Q 2023). Profit margin: 12% (down from 20% in 2Q 2023). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings. Annonce • Jun 29
Valiant Co.,Ltd to Report First Half, 2024 Results on Aug 22, 2024 Valiant Co.,Ltd announced that they will report first half, 2024 results on Aug 22, 2024 Declared Dividend • Jun 01
Dividend of CN¥0.30 announced Shareholders will receive a dividend of CN¥0.30. Ex-date: 6th June 2024 Payment date: 6th June 2024 Dividend yield will be 2.6%, which is about the same as the industry average. Sustainability & Growth Dividend is covered by earnings (39% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 15% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 61% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Annonce • May 31
Valiant Co.,Ltd Announces 2023 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 06 June 2024 Valiant Co.,Ltd announced 2023 final profit distribution plan to be implemented (A shares) of Cash dividend/10 shares (tax included) is CNY 3.00000000, Record date is 05 June 2024, Ex-date: 06 June 2024, Payment date is 06 June 2024. Annonce • Apr 21
Valiant Co.,Ltd, Annual General Meeting, May 16, 2024 Valiant Co.,Ltd, Annual General Meeting, May 16, 2024, at 14:00 China Standard Time. Location: The Company's Meeting Room, Yantai, Shandong China Reported Earnings • Apr 20
First quarter 2024 earnings released: EPS: CN¥0.11 (vs CN¥0.19 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.11 (down from CN¥0.19 in 1Q 2023). Revenue: CN¥937.9m (down 9.2% from 1Q 2023). Net income: CN¥98.3m (down 44% from 1Q 2023). Profit margin: 11% (down from 17% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Annonce • Mar 30
Valiant Co.,Ltd to Report Q1, 2024 Results on Apr 20, 2024 Valiant Co.,Ltd announced that they will report Q1, 2024 results on Apr 20, 2024 Valuation Update With 7 Day Price Move • Feb 05
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥11.78, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 12x in the Chemicals industry in China. Total loss to shareholders of 40% over the past three years. Annonce • Dec 30
Valiant Co.,Ltd to Report Fiscal Year 2023 Results on Apr 20, 2024 Valiant Co.,Ltd announced that they will report fiscal year 2023 results on Apr 20, 2024 Reported Earnings • Nov 01
Third quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥0.17 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.20 (up from CN¥0.17 in 3Q 2022). Revenue: CN¥1.10b (down 12% from 3Q 2022). Net income: CN¥186.1m (up 22% from 3Q 2022). Profit margin: 17% (up from 12% in 3Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Annonce • Oct 19
Valiant Co.,Ltd Announces Board Appointments Valiant Co.,Ltd held its 2nd Extraordinary General Meeting of 2023 on 17 October 2023, approved the appointment of Zhu Caifei and Zhang Yun as non-independent directors. Reported Earnings • Aug 19
Second quarter 2023 earnings released: EPS: CN¥0.24 (vs CN¥0.29 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.24 (down from CN¥0.29 in 2Q 2022). Revenue: CN¥1.04b (down 14% from 2Q 2022). Net income: CN¥212.8m (down 18% from 2Q 2022). Profit margin: 20% (in line with 2Q 2022). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Board Change • Jul 27
High number of new and inexperienced directors There are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 2 experienced directors. 2 highly experienced directors. Member of Supervisory Board Zhenjian Gu is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Annonce • Jul 23
Valiant Co.,Ltd Approves Board Elections Valiant Co.,Ltd at its Extraordinary General Meeting held on 20 July 2023 approved the election of Tang Meng, Yang Yaowu and Yang Xiaoyue as non-independent directors. Buying Opportunity • Jul 05
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 3.5%. The fair value is estimated to be CN¥21.92, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Earnings per share has grown by 16%. Revenue is forecast to grow by 30% in 2 years. Earnings is forecast to grow by 63% in the next 2 years. Annonce • Jul 01
Valiant Co.,Ltd to Report First Half, 2023 Results on Aug 19, 2023 Valiant Co.,Ltd announced that they will report first half, 2023 results on Aug 19, 2023 Buying Opportunity • Jun 09
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 9.4%. The fair value is estimated to be CN¥20.11, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Earnings per share has grown by 16%. Revenue is forecast to grow by 30% in 2 years. Earnings is forecast to grow by 63% in the next 2 years. Annonce • Jun 03
Valiant Co.,Ltd Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 09 June 2023 Valiant Co.,Ltd announced final profit distribution plan to be implemented on A shares as cash dividend per ten shares (tax included) of CNY 2.95000000 for the year 2022, payable on 09 June 2023. Record date is 08 June 2023. Ex-date is 09 June 2023. Buying Opportunity • May 16
Now 23% undervalued after recent price drop Over the last 90 days, the stock is down 18%. The fair value is estimated to be CN¥20.30, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Earnings per share has grown by 16%. Revenue is forecast to grow by 30% in 2 years. Earnings is forecast to grow by 64% in the next 2 years. Reported Earnings • Apr 24
First quarter 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.25 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.19 (down from CN¥0.25 in 1Q 2022). Revenue: CN¥1.03b (down 25% from 1Q 2022). Net income: CN¥176.6m (down 24% from 1Q 2022). Profit margin: 17% (in line with 1Q 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Feb 01
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥18.82, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 17x in the Chemicals industry in China. Total returns to shareholders of 32% over the past three years. Board Change • Nov 16
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 2 experienced directors. 3 highly experienced directors. Member of Supervisory Board Tianxiao Hu is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Oct 29
Third quarter 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.21 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.17 (down from CN¥0.21 in 3Q 2021). Revenue: CN¥1.26b (down 11% from 3Q 2021). Net income: CN¥153.0m (down 20% from 3Q 2021). Profit margin: 12% (down from 14% in 3Q 2021). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 21
Second quarter 2022 earnings released: EPS: CN¥0.29 (vs CN¥0.19 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.29 (up from CN¥0.19 in 2Q 2021). Revenue: CN¥1.22b (up 19% from 2Q 2021). Net income: CN¥258.1m (up 53% from 2Q 2021). Profit margin: 21% (up from 17% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 14%, compared to a 41% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 16% per year whereas the company’s share price has increased by 18% per year. Board Change • May 29
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Ying Guo was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 29
First quarter 2022 earnings released: EPS: CN¥0.25 (vs CN¥0.14 in 1Q 2021) First quarter 2022 results: EPS: CN¥0.25 (up from CN¥0.14 in 1Q 2021). Revenue: CN¥1.37b (up 74% from 1Q 2021). Net income: CN¥232.8m (up 77% from 1Q 2021). Profit margin: 17% (in line with 1Q 2021). Over the next year, revenue is forecast to grow 16%, compared to a 42% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 12% per year whereas the company’s share price has increased by 14% per year. Board Change • Apr 27
High number of new directors There are 8 new directors who have joined the board in the last 3 years. Director Wei Li was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Mar 29
Full year 2021 earnings released: EPS: CN¥0.69 (vs CN¥0.56 in FY 2020) Full year 2021 results: EPS: CN¥0.69 (up from CN¥0.56 in FY 2020). Revenue: CN¥4.36b (up 49% from FY 2020). Net income: CN¥626.7m (up 24% from FY 2020). Profit margin: 14% (down from 17% in FY 2020). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 26%, compared to a 47% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 10% per year whereas the company’s share price has increased by 14% per year. Buying Opportunity • Feb 12
Now 22% undervalued The stock has been flat over the last 90 days. The fair value is estimated to be CN¥26.16, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% per annum over the last 3 years. Earnings per share has grown by 11% per annum over the last 3 years. Buying Opportunity • Jan 26
Now 21% undervalued Over the last 90 days, the stock is up 1.6%. The fair value is estimated to be CN¥26.28, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% per annum over the last 3 years. Earnings per share has grown by 11% per annum over the last 3 years. Valuation Update With 7 Day Price Move • Nov 19
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥24.21, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 20x in the Chemicals industry in China. Total returns to shareholders of 173% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥26.03 per share. Reported Earnings • Oct 26
Third quarter 2021 earnings released: EPS CN¥0.21 (vs CN¥0.15 in 3Q 2020) The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: CN¥1.42b (up 101% from 3Q 2020). Net income: CN¥191.5m (up 45% from 3Q 2020). Profit margin: 14% (down from 19% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥17.55, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 19x in the Chemicals industry in China. Total returns to shareholders of 86% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥26.58 per share. Valuation Update With 7 Day Price Move • Aug 26
Investor sentiment improved over the past week After last week's 19% share price gain to CN¥21.52, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 20x in the Chemicals industry in China. Total returns to shareholders of 169% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥24.22 per share. Reported Earnings • Aug 22
Second quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.10 in 2Q 2020) The company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2021 results: Revenue: CN¥1.02b (up 77% from 2Q 2020). Net income: CN¥169.3m (up 84% from 2Q 2020). Profit margin: 17% (in line with 2Q 2020). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 35% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Jul 22
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥18.56, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 20x in the Chemicals industry in China. Total returns to shareholders of 140% over the past three years. Reported Earnings • Apr 29
First quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.14 in 1Q 2020) The company reported a solid first quarter result with improved earnings and revenues, although profit margins were weaker. First quarter 2021 results: Revenue: CN¥786.7m (up 18% from 1Q 2020). Net income: CN¥131.8m (up 6.1% from 1Q 2020). Profit margin: 17% (down from 19% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Mar 26
Full year 2020 earnings released: EPS CN¥0.56 (vs CN¥0.56 in FY 2019) The company reported a solid full year result with improved revenues, although earnings and profit margins were flat. Full year 2020 results: Revenue: CN¥2.92b (up 1.7% from FY 2019). Net income: CN¥504.7m (flat on FY 2019). Profit margin: 17% (in line with FY 2019). Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 14% per year. Valuation Update With 7 Day Price Move • Mar 10
Investor sentiment deteriorated over the past week After last week's 15% share price decline to CN¥17.10, the stock is trading at a trailing P/E ratio of 31.7x, down from the previous P/E ratio of 37.5x. This compares to an average P/E of 35x in the Chemicals industry in China. Total returns to shareholders over the past three years are 60%. Is New 90 Day High Low • Mar 06
New 90-day low: CN¥18.68 The company is down 6.0% from its price of CN¥19.95 on 04 December 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥4.16 per share. Is New 90 Day High Low • Jan 25
New 90-day high: CN¥24.71 The company is up 36% from its price of CN¥18.17 on 28 October 2020. The Chinese market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 25% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥4.14 per share. Is New 90 Day High Low • Jan 07
New 90-day high: CN¥22.27 The company is up 18% from its price of CN¥18.89 on 09 October 2020. The Chinese market is up 11% over the last 90 days, indicating the company outperformed over that time. However, its price trend is similar to the Chemicals industry, which is also up 18% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥3.89 per share. Is New 90 Day High Low • Dec 21
New 90-day high: CN¥21.29 The company is up 13% from its price of CN¥18.82 on 23 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥3.46 per share. Is New 90 Day High Low • Dec 03
New 90-day high: CN¥20.51 The company is up 10.0% from its price of CN¥18.66 on 04 September 2020. The Chinese market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥3.08 per share. Reported Earnings • Oct 25
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥488.8m, down 3.1% from the prior year. Total revenue was CN¥2.88b over the last 12 months, up 5.5% from the prior year. Is New 90 Day High Low • Oct 23
New 90-day low: CN¥16.38 The company is down 1.0% from its price of CN¥16.55 on 24 July 2020. The Chinese market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥26.87 per share. Annonce • Oct 17
Valiant Co.,Ltd to Report Q3, 2020 Results on Oct 24, 2020 Valiant Co.,Ltd announced that they will report Q3, 2020 results on Oct 24, 2020 Annonce • Jul 18
Valiant Co.,Ltd to Report First Half, 2020 Results on Aug 15, 2020 Valiant Co.,Ltd announced that they will report first half, 2020 results on Aug 15, 2020